Ocular Therapeutix Inc (NAS:OCUL)
$ 10.855 0.255 (2.41%) Market Cap: 1.69 Bil Enterprise Value: 1.31 Bil PE Ratio: 0 PB Ratio: 4.47 GF Score: 66/100

Ocular Therapeutix Inc - Announces Results Of Phase 3 Clinical Trial of Dextenza Transcript

Apr 28, 2020 / 12:30PM GMT
Release Date Price: $5.81 (+2.65%)
Operator

Thank you for standing by, and welcome to the Ocular Therapeutix Announces Top Line Results of Phase III Clinical Trial of DEXTENZA for the Treatment of Allergic Conjunctivitis Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Mr. Donald Notman, Chief Financial Officer. Thank you. Please go ahead, sir.

Donald Notman
Ocular Therapeutix, Inc. - CFO

Thank you, Dilem. Good morning, everyone, and thank you for joining us to discuss the top line results from our Phase III clinical trial of DEXTENZA for the treatment of allergic conjunctivitis. The press release and a copy of today's presentation can be accessed on the Investors portion of our website at investors.ocutx.com.

Leading the call today will be Antony Mattessich, our President and Chief Executive Officer, who will provide a summary. Also speaking on the call today will be Dr. Michael Goldstein, our Chief Medical Officer, who will give an update

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot